Petrichor Healthcare Capital Management

Geneoscopy, LLC is a diagnostics company based in Saint Louis, Missouri, that specializes in non-invasive colorectal cancer screening and gastrointestinal disease management. Founded in 2015, Geneoscopy has developed a platform technology that utilizes stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the downstream effects of cancer-causing DNA mutations. The company's diagnostic test aims to improve compliance with colorectal cancer screening, facilitate early-stage detection of neoplasms, and ultimately reduce morbidity and mortality associated with the disease. Additionally, Geneoscopy is exploring other applications of its technology for various gastrointestinal conditions, aiming to provide reliable alternatives to traditional invasive procedures like colonoscopy.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania, established in 2015. The company specializes in developing and commercializing targeted therapies for serious and rare genetic skin diseases, focusing on addressing the root causes of these conditions. Its lead product candidate, QTORIN, is an anhydrous gel formulated to ensure drug stability at room temperature while enabling effective distribution into skin layers where various dermatologic pathologies occur. Palvella Therapeutics is committed to serving patient populations that have been overlooked, with an initial emphasis on conditions such as microcystic lymphatic malformations and cutaneous venous malformations, leveraging its patented QTORIN platform to advance its therapeutic pipeline.

Evergreen Theragnostics, Inc. is a contract development and manufacturing organization based in Jersey City, New Jersey, established in 2019. It specializes in radiopharmaceutical development and offers a comprehensive suite of services that includes manufacturing, technology transfer, method validation, regulatory support, logistics, and commercialization. The company is dedicated to enhancing treatment options for cancer patients by providing reliable manufacturing services for both therapeutic and diagnostic radiopharmaceuticals. With a team of experts experienced in theragnostic commercialization and regulatory management, Evergreen Theragnostics positions itself as a key partner for organizations seeking to navigate the complexities of radiopharmaceutical development and production.

Avalo Therapeutics is a clinical-stage biopharmaceutical company that focuses on developing highly targeted therapeutics for immune dysregulation and other areas of significant unmet clinical need. The company employs a precision medicine approach in its research and development efforts. Its lead asset, AVTX-009, is an anti-IL-1B monoclonal antibody designed to address inflammatory diseases. In addition to AVTX-009, Avalo's pipeline includes quisovalimab, an anti-LIGHT monoclonal antibody, and AVTX-008, a BTLA agonist fusion protein, which further exemplify its commitment to advancing innovative treatments for complex medical conditions.

Fennec Pharmaceuticals Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, that focuses on developing treatments for cancer-related conditions, particularly in pediatric patients. The company’s lead product, PEDMARK, is a novel formulation of Sodium Thiosulfate designed to prevent cisplatin-induced ototoxicity, a common and serious side effect of certain chemotherapy treatments that can lead to permanent hearing loss in children. Fennec Pharmaceuticals is currently advancing PEDMARK through clinical trials, having completed Phase III studies to assess its efficacy and safety. Founded in 1996 and formerly known as Adherex Technologies Inc., the company aims to improve the quality of life for children undergoing chemotherapy by mitigating the risk of hearing loss.

Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.

VERO Biotech LLC is a biopharmaceutical company focused on developing and commercializing innovative products for patients with pulmonary and cardiac conditions. The company specializes in inhaled nitric oxide (NO) delivery systems, which are designed for both hospital settings and longer-term home use. Utilizing its proprietary GeNOsyl drug delivery technology, VERO Biotech offers a user-friendly solution that includes a single-use drug cassette coupled with a portable console or wearable controller. This technology aims to provide a safe and consistent administration of nitric oxide for various therapeutic applications, addressing unmet medical needs such as pulmonary arterial hypertension and hypoxic respiratory failure in newborns. Founded in 2006 and based in Atlanta, Georgia, VERO Biotech was previously known as GeNO LLC.

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania, established in 2015. The company specializes in developing and commercializing targeted therapies for serious and rare genetic skin diseases, focusing on addressing the root causes of these conditions. Its lead product candidate, QTORIN, is an anhydrous gel formulated to ensure drug stability at room temperature while enabling effective distribution into skin layers where various dermatologic pathologies occur. Palvella Therapeutics is committed to serving patient populations that have been overlooked, with an initial emphasis on conditions such as microcystic lymphatic malformations and cutaneous venous malformations, leveraging its patented QTORIN platform to advance its therapeutic pipeline.

Fennec Pharmaceuticals Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, that focuses on developing treatments for cancer-related conditions, particularly in pediatric patients. The company’s lead product, PEDMARK, is a novel formulation of Sodium Thiosulfate designed to prevent cisplatin-induced ototoxicity, a common and serious side effect of certain chemotherapy treatments that can lead to permanent hearing loss in children. Fennec Pharmaceuticals is currently advancing PEDMARK through clinical trials, having completed Phase III studies to assess its efficacy and safety. Founded in 1996 and formerly known as Adherex Technologies Inc., the company aims to improve the quality of life for children undergoing chemotherapy by mitigating the risk of hearing loss.

Fennec Pharmaceuticals Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, that focuses on developing treatments for cancer-related conditions, particularly in pediatric patients. The company’s lead product, PEDMARK, is a novel formulation of Sodium Thiosulfate designed to prevent cisplatin-induced ototoxicity, a common and serious side effect of certain chemotherapy treatments that can lead to permanent hearing loss in children. Fennec Pharmaceuticals is currently advancing PEDMARK through clinical trials, having completed Phase III studies to assess its efficacy and safety. Founded in 1996 and formerly known as Adherex Technologies Inc., the company aims to improve the quality of life for children undergoing chemotherapy by mitigating the risk of hearing loss.

Fennec Pharmaceuticals Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, that focuses on developing treatments for cancer-related conditions, particularly in pediatric patients. The company’s lead product, PEDMARK, is a novel formulation of Sodium Thiosulfate designed to prevent cisplatin-induced ototoxicity, a common and serious side effect of certain chemotherapy treatments that can lead to permanent hearing loss in children. Fennec Pharmaceuticals is currently advancing PEDMARK through clinical trials, having completed Phase III studies to assess its efficacy and safety. Founded in 1996 and formerly known as Adherex Technologies Inc., the company aims to improve the quality of life for children undergoing chemotherapy by mitigating the risk of hearing loss.

Tourmaline Bio is a clinical biotechnology company focused on developing transformative medicines aimed at improving the lives of patients suffering from immune diseases. The company is in the late stages of clinical development and is centered on its lead product candidate, TOUR006, a fully human monoclonal antibody designed to selectively target interleukin-6 (IL-6), a significant proinflammatory cytokine implicated in various autoimmune and inflammatory disorders. The IL-6 antibody class has a well-established history, with over two decades of clinical and commercial experience, having successfully treated more than a million patients with diverse autoimmune and inflammatory conditions. Through its innovative research, Tourmaline Bio seeks to address the unmet medical needs of patients affected by life-altering immune diseases.

Aurion Biotechnologies is a clinical-stage biotech company focused on developing advanced therapies for ocular diseases, particularly those leading to blindness. Based in Seattle, Boston, and Tokyo, the company aims to transform the lives of millions by restoring vision through innovative cell therapies. Its lead candidate targets corneal edema and is one of the first clinically validated cell therapies in corneal care. The process involves culturing healthy cells from a donor cornea using a proprietary method, allowing cells from a single donor to potentially treat over 100 recipient eyes. Clinical trials in Japan have shown that patients experience significant and lasting improvements in corneal health indicators, including visual acuity and corneal thickness.

Leukocare is a biotechnology company focused on developing protein stabilizing technologies aimed at reducing systemic inflammation during cardiac surgery. The company leverages its expertise in formulation development alongside bioinformatics and artificial intelligence to create innovative solutions for biopharmaceuticals, viral vectors, vaccines, and biofunctionalized devices. By employing an antibody that reduces leukocyte activity in extracorporeal blood circuits, Leukocare enables patients to benefit from minimized inflammation during surgical procedures.

Leukocare is a biotechnology company focused on developing protein stabilizing technologies aimed at reducing systemic inflammation during cardiac surgery. The company leverages its expertise in formulation development alongside bioinformatics and artificial intelligence to create innovative solutions for biopharmaceuticals, viral vectors, vaccines, and biofunctionalized devices. By employing an antibody that reduces leukocyte activity in extracorporeal blood circuits, Leukocare enables patients to benefit from minimized inflammation during surgical procedures.

ITM Isotopen Technologien München AG is a biotechnology and radiopharmaceutical company based in Garching, Germany, focusing on the development, manufacturing, and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for cancer treatment. Established in 2004, ITM has built a robust global supply network and accomplished GMP manufacturing capabilities. The company offers a range of products, including EndolucinBeta, a radiopharmaceutical precursor for targeted radionuclide therapy, as well as radionuclides like 225Ac and 213Bi. Additionally, ITM develops automated systems for synthesizing radiolabeled biomolecules and provides GMP radiolabeling services. With a growing portfolio of innovative treatments and partnerships, ITM aims to enhance patient outcomes and quality of life in oncology, specifically addressing conditions such as neuroendocrine cancers and bone metastases while minimizing side effects.

ClearPoint Neuro, Inc., established in 1998 and headquartered in Irvine, California, operates as a medical device company specializing in minimally invasive neurosurgical procedures guided by direct magnetic resonance imaging (MRI). The company's primary product is the ClearPoint system, designed for precise insertion of catheters, electrodes, and laser fibers to treat neurological conditions such as deep-brain stimulation and biopsy. Additionally, ClearPoint Neuro has product candidates like the ClearTrace system for cardiac applications, aiming to expand its offerings in MRI-guided procedures. The company collaborates with renowned institutions like Johns Hopkins University and Mayo Clinic to develop innovative therapies and has a strategic focus on improving patient outcomes through precise neurological interventions.

ClearPoint Neuro, Inc., established in 1998 and headquartered in Irvine, California, operates as a medical device company specializing in minimally invasive neurosurgical procedures guided by direct magnetic resonance imaging (MRI). The company's primary product is the ClearPoint system, designed for precise insertion of catheters, electrodes, and laser fibers to treat neurological conditions such as deep-brain stimulation and biopsy. Additionally, ClearPoint Neuro has product candidates like the ClearTrace system for cardiac applications, aiming to expand its offerings in MRI-guided procedures. The company collaborates with renowned institutions like Johns Hopkins University and Mayo Clinic to develop innovative therapies and has a strategic focus on improving patient outcomes through precise neurological interventions.

Persivia Inc. is a healthcare IT company based in Marlborough, Massachusetts, that specializes in providing an AI-driven platform for managing value-based care programs. Established in 2005, the company offers a population health management solution designed for hospitals, payers, and healthcare providers. Persivia's platform integrates clinical, socioeconomic, and claims data to create a comprehensive view of patient care, enabling personalized treatment and improved health outcomes. The platform supports various functionalities, including chronic care management, quality reporting, care coordination, and clinical analytics, facilitating compliance with government regulations and enhancing the management of population risk. Through its innovative technology, Persivia aims to improve care quality while reducing costs for healthcare organizations.

CorneaGen is a mission-driven company focused on innovating cornea care to eliminate corneal blindness globally. It develops advanced medical devices, biologics, and therapeutics aimed at improving the treatment and care provided by corneal surgeons. CorneaGen offers a comprehensive range of services, including the delivery of high-quality tissue, surgeon education, and advocacy for patient access and reimbursement policies. By equipping eye surgeons with innovative tools and resources, CorneaGen strives to restore sight for individuals suffering from corneal conditions, thereby transforming the landscape of corneal surgery and enhancing patient outcomes.

CorneaGen is a mission-driven company focused on innovating cornea care to eliminate corneal blindness globally. It develops advanced medical devices, biologics, and therapeutics aimed at improving the treatment and care provided by corneal surgeons. CorneaGen offers a comprehensive range of services, including the delivery of high-quality tissue, surgeon education, and advocacy for patient access and reimbursement policies. By equipping eye surgeons with innovative tools and resources, CorneaGen strives to restore sight for individuals suffering from corneal conditions, thereby transforming the landscape of corneal surgery and enhancing patient outcomes.